| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $2 ) |
| | 2022 | 2019 | SCALMIBIO, INC | 4598 17TH ST | SAN FRANCISCO | CA | 94114-1809 | SAN FRANCISCO | USA | R43CA239872 | Development of a universal prodrug approach for antibody based therapeutics | 000 | 1 | NIH | 9/26/2022 | $2 |
|
| Issue Date FY: 2021 ( Subtotal = -$12 ) |
| | 2021 | 2019 | SCALMIBIO, INC | 4598 17TH ST | SAN FRANCISCO | CA | 94114-1809 | SAN FRANCISCO | USA | R43CA239872 | Development of a universal prodrug approach for antibody based therapeutics | 000 | 1 | NIH | 7/9/2021 | -$12 |
|
| Issue Date FY: 2019 ( Subtotal = $299,967 ) |
| | 2019 | 2019 | SCALMIBIO, INC | 4598 17TH ST | SAN FRANCISCO | CA | 94114-1809 | SAN FRANCISCO | USA | R43CA239872 | Development of a universal prodrug approach for antibody based therapeutics | 000 | 1 | NIH | 3/8/2019 | $299,967 |
|
|
